- ►fafp.org [PDF] RA DeFronzo - Medical Clinics of North America, 2004 - Elsevier A discussion of the pathogenesis of type 2 diabetes mellitus must start with a
review of mechanisms involved in the maintenance of normal glucose homeostasis
in the basal or postabsorptive state (10–12 h overnight fast) and ... Cited by 692 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 283 - Related articles - All 13 versions
- ►endojournals.org L Farilla, H Hui, C Bertolotto, E Kang, A Bulotta … - Endocrinology, 2002 - Endocrine Soc A constant remodeling of islet cell mass mediated by proliferative and apoptotic
stimuli ensures a dynamic response to a changing demand for insulin. In this
study, we investigated the effect of glucagon-like peptide-1 (GLP-1) in ... Cited by 193 - Related articles - BL Direct - All 6 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential
interest for the treatment of type 2 diabetes. To evaluate actions of NN2211, a
long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, ... Cited by 174 - Related articles - BL Direct - All 6 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 173 - Related articles - All 25 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among
193 outpatients with type 2 diabetes. The mean age was 56.6 years and the ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for
treating type 2 diabetes. We explored the effect of short-term (1 week)
treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics ... Cited by 168 - Related articles - BL Direct - All 8 versions
AM Lambeir, C Durinx, S Scharpé, I De … - Critical reviews in clinical laboratory sciences, 2003 - informahealthcare.com Laboratory of Medical Biochemistry, University of Antwerp, Universiteitsplein 1,
Wilrijk, Belgium ... Referee: Dr. Albert Adam, Faculté de Pharmace,
Université de Montréal, 2900 Blvd. Edouard—Montpetit, CP succursale ... Cited by 166 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
T Vilsbøll, JJ Holst - Diabetologia, 2004 - Springer When glucose is taken orally, insulin secretion is stim- ulated much more than
it is when glucose is infused intravenously so as to result in similar glucose
con- centrations. This effect, which is called the incretin ef- fect and is ... Cited by 145 - Related articles - BL Direct - All 7 versions
